- Home
- HWH vs MRKR Comparison
HWH vs MRKR Comparison
Compare HWH & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWH
- MRKR
- Stock Information
- Founded
- HWH 2021
- MRKR N/A
- Country
- HWH United States
- MRKR United States
- Employees
- HWH N/A
- MRKR N/A
- Industry
- HWH Other Pharmaceuticals
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- HWH Health Care
- MRKR Health Care
- Exchange
- HWH Nasdaq
- MRKR Nasdaq
- Market Cap
- HWH 10.1M
- MRKR 11.6M
- IPO Year
- HWH N/A
- MRKR N/A
- Fundamental
- Price
- HWH $2.75
- MRKR $1.06
- Analyst Decision
- HWH
- MRKR Strong Buy
- Analyst Count
- HWH 0
- MRKR 3
- Target Price
- HWH N/A
- MRKR $13.17
- AVG Volume (30 Days)
- HWH 158.2K
- MRKR 325.1K
- Earning Date
- HWH 11-11-2025
- MRKR 11-13-2025
- Dividend Yield
- HWH N/A
- MRKR N/A
- EPS Growth
- HWH N/A
- MRKR N/A
- EPS
- HWH N/A
- MRKR N/A
- Revenue
- HWH $1,238,173.00
- MRKR $5,388,071.00
- Revenue This Year
- HWH N/A
- MRKR N/A
- Revenue Next Year
- HWH N/A
- MRKR $9.35
- P/E Ratio
- HWH N/A
- MRKR N/A
- Revenue Growth
- HWH 17.28
- MRKR 44.55
- 52 Week Low
- HWH $0.90
- MRKR $0.81
- 52 Week High
- HWH $7.77
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- HWH 48.54
- MRKR 55.45
- Support Level
- HWH $2.66
- MRKR $0.85
- Resistance Level
- HWH $3.12
- MRKR $0.96
- Average True Range (ATR)
- HWH 0.19
- MRKR 0.07
- MACD
- HWH -0.06
- MRKR 0.03
- Stochastic Oscillator
- HWH 25.00
- MRKR 69.64
About HWH HWH International Inc.
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.